Related references
Note: Only part of the references are listed.Using dopamine research to generate rational cannabinoid drug policy
G. C. Loewinger et al.
DRUG TESTING AND ANALYSIS (2013)
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Amir Englund et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study
Michael C. Mithoefer et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin
R. L. Carhart-Harris et al.
BRITISH JOURNAL OF PSYCHIATRY (2012)
Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence
Torsten Passie et al.
DRUG TESTING AND ANALYSIS (2012)
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
John Peter Zajicek et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?
Ruth Weissenborn et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Teri S. Krebs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Methoxetamine: From drug of abuse to rapid-acting antidepressant
M. Coppola et al.
MEDICAL HYPOTHESES (2012)
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Robin L. Carhart-Harris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Psychiatry, The Pharmaceutical Industry, and The Road to Better Therapeutics
H. Christian Fibiger
SCHIZOPHRENIA BULLETIN (2012)
State of the Art Treatments for Cannabis Dependence
Itai Danovitch et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2012)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time
Philippe Huot et al.
JOURNAL OF NEUROSCIENCE (2011)
The safety and efficacy of ± 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
Michael C. Mithoefer et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Serotonergic regulation of neuronal excitability in the prefrontal cortex
Rodrigo Andrade
NEUROPHARMACOLOGY (2011)
The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI)
Shahaf Edut et al.
PSYCHOPHARMACOLOGY (2011)
Is Ecstasy an Empathogen? Effects of ±3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others
Gillinder Bedi et al.
BIOLOGICAL PSYCHIATRY (2010)
The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series
Matthias Karst et al.
CEPHALALGIA (2010)
An index of fatal toxicity for drugs of misuse
Leslie A. King et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2010)
Drug harms in the UK: a multicriteria decision analysis
David J. Nutt et al.
LANCET (2010)
Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis
Celia J. A. Morgan et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Opioid dependence treatment: options in pharmacotherapy
Angela L. Stotts et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Equasy - An overlooked addiction with implications for the current debate on drug harms
D. J. Nutt
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Cortical circuits for perceptual inference
Karl J. Friston et al.
NEURAL NETWORKS (2009)
Effects of MDMA on sociability and neural response to social threat and social reward
Gillinder Bedi et al.
PSYCHOPHARMACOLOGY (2009)
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
R. R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
The psychoactive plant cannabinoid, Delta(9)-tetrahydrocannabinol, is antagonized by Delta(8)- and Delta(9)-tetrahydrocannabivarin in mice in vivo
R. G. Pertwee et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Development of a rational scale to assess the harm of drugs of potential misuse
David Nutt et al.
LANCET (2007)
Cannabis in painful HIV-associated sensory neuropathy - A randomized placebo-controlled trial
D. I. Abrams et al.
NEUROLOGY (2007)
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Francisco A. Moreno et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. R. Griffiths et al.
PSYCHOPHARMACOLOGY (2006)
Response of cluster headache to psilocybin and LSD
R. Andrew Sewell et al.
NEUROLOGY (2006)
The pharmacology of cannabinoid receptors and their ligands: an overview
RG Pertwee
INTERNATIONAL JOURNAL OF OBESITY (2006)
A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response
AR Green et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Severe Dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (ecstasy)
GA Ricaurte et al.
SCIENCE (2002)
Seizure control as an indicator of therapeutic usefulness
S Wiebe
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2000)
Share Paper
